HKD 0.38
(-1.32%)
Year | EBITDA | EBITDA Growth |
---|---|---|
2023 | 36.81 Million CNY | -26.99% |
2022 | 44.16 Million CNY | -11.42% |
2021 | 49.85 Million CNY | 8.2% |
2020 | 43.16 Million CNY | 67.47% |
2019 | 29.39 Million HKD | -38.91% |
2018 | 48.11 Million HKD | 0.0% |
Year | EBITDA | EBITDA Growth |
---|---|---|
2024 Q2 | 13.81 Million HKD | 0.0% |
2023 Q1 | 11.14 Million HKD | -57.64% |
2023 Q3 | 9.2 Million HKD | -53.88% |
2023 Q4 | 14.6 Million HKD | 58.6% |
2023 Q2 | 19.96 Million HKD | 79.11% |
2023 FY | - CNY | -26.99% |
2022 Q3 | 12.95 Million HKD | -36.91% |
2022 FY | - CNY | -11.42% |
2022 Q4 | 26.31 Million HKD | 103.16% |
2022 Q2 | 20.53 Million HKD | 0.0% |
2021 FY | - CNY | 8.2% |
2020 FY | - CNY | 67.47% |
2019 FY | - HKD | -38.91% |
2018 FY | - HKD | 0.0% |
Name | EBITDA | EBITDA Difference |
---|---|---|
Anxian Yuan China Holdings Limited | 106.4 Million HKD | 65.405% |
Water Oasis Group Limited | 345.33 Million HKD | 89.341% |
Miricor Enterprises Holdings Limited | 86.61 Million HKD | 57.504% |
Perfect Medical Health Management Limited | 577.56 Million HKD | 93.627% |
Fameglow Holdings Limited | 93.66 Million HKD | 60.699% |